Enzo Biochem (NYSE:ENZ) Announces Earnings Results

Enzo Biochem (NYSE:ENZ) announced its quarterly earnings results on Monday. The medical research company reported ($0.02) EPS for the quarter, Zacks reports. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%. The business had revenue of $7.33 million for the quarter.

Enzo Biochem Stock Up 7.2 %

NYSE ENZ opened at $0.50 on Wednesday. Enzo Biochem has a 52 week low of $0.41 and a 52 week high of $1.30. The firm’s 50-day simple moving average is $0.56 and its two-hundred day simple moving average is $0.87.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Enzo Biochem in a research note on Saturday. They issued a “hold” rating for the company.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.